The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NGSCUP: Phase II trial of site-specific treatment based on gene expression and mutation profiling by next generation sequencing (NGS) for patients (pts) with cancer of unknown primary site (CUP).
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hironobu Minami
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Takara Bio; Takeda
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Kohei Akiyoshi
No Relationships to Disclose
 
Yoshihiko Segawa
Honoraria - Taiho Pharmaceutical
Research Funding - Eisai; Taiho Pharmaceutical
 
Hiroki Ueda
No Relationships to Disclose
 
Yasuo Iwamoto
No Relationships to Disclose
 
Chihiro Nakayama Kondoh
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Merck Sharp & Dohme; Nippon Shinyaku; Sanofi; Takeda
 
Koji Matsumoto
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD K.K; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Shin Takahashi
Honoraria - Asahi Kasei; Chugai Pharma; Daiichi Sankyo; Medicon; Merck Serono; Nihonkayaku; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Research Funding - Merck Serono; Ono Pharmaceutical
 
Hisateru Yasui
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Taiho Pharmaceutical; TERUMO; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Toshiyuki Sawa
No Relationships to Disclose
 
Yusuke Onozawa
Honoraria - Bayer
 
Yasutaka Chiba
Honoraria - Chugai Pharma
 
Yosuke Togashi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical
 
Kazuko Sakai
Honoraria - AstraZeneca; Bio-Rad; Chugai Pharma; Roche; SRL Diagnostics
 
Yoshihiko Fujita
No Relationships to Disclose
 
Shuta Tomida
Speakers' Bureau - Bristol-Myers Squibb Japan; Ono Pharmaceutical
 
Kazuto Nishio
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Guardant Health; Life Technologies; Life Technologies; Lilly Japan; MSD K.K; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Roche; Sanofi; Solasia Pharma; SymBio Pharmaceuticals; Yakult Honsha
 
Kazuhiko Nakagawa
Honoraria - Abbvie; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Medicus Shuppan Publishers; Merck; MSD K.K; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Consulting or Advisory Role - Kyorin; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); ICON Clinical Research (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)